A new research advance targets a key limitation of current cancer biomarker workflows by pushing toward liquid-biopsy-style profiling of antitumor immune responses. The report emphasizes that tissue biopsy remains the clinical gold standard for immune architecture mapping, including spatial patterns linked to immunotherapy responsiveness. It argues that repeated tumor sampling is invasive and often impractical, motivating methods that can capture immune state signatures without serial tissue procurement. The focus is on profiling immune responses in a way that reflects the spatial and functional context that guides treatment decisions. For translational teams, the piece frames liquid biopsy development as an immunology problem—how to measure the right immune features with enough resolution to predict and guide therapies.